tgAAC94 gene therapy / Armata, Amgen - LARVOL DELTA

Study of Intra-articular Delivery of tgAAC94 in Inflammatory Arthritis Subjects (clinicaltrials.gov) - P1/2; N=120; Completed; Sponsor: Targeted Genetics Corporation; Active, not recruiting ➔ Completed

Clinical • Trial completion • Ankylosing Spondylitis • Gene Therapies • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies • MRI • TNFA